Drug safety evaluation of pregabalin

Bibliography

• Oteri A, Trifiro G, Gagliostro MS, Prescribing pattern of anti-epileptic drugs in an Italian setting of elderly outpatients: a population-based study during 2004-07. Br J Clin Pharmacol 2010;70(4):514-22
   PubMed Web of Science ®Google Scholar
• Bauer CS, Nieto-Rostro M, Rahman W, The increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin. J Neurosci 2009;29(13):4076-88
   PubMed Web of Science ®Google Scholar
• Eroglu C, Allen NJ, Susman MW, Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell 2009;139(2):380-92
   PubMed Web of Science ®Google Scholar
• Moulin DE, Clark AJ, Gilron I, Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007;12(1):13-21
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O'Connor AB, Audette J, Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85(3 Suppl):S3-14
   PubMed Web of Science ®Google Scholar
• O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009;122(10 Suppl):S22-32
   PubMed Web of Science ®Google Scholar
• Treede RD, Jensen TS, Campbell JN, Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70(18):1630-5
   PubMed Web of Science ®Google Scholar
• Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain 2006;7(4):281-9
   PubMed Web of Science ®Google Scholar
• Bouhassira D, Lanteri-Minet M, Attal N, Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136(3):380-7
   PubMed Web of Science ®Google Scholar
• Toth C, Lander J, Wiebe S. The prevalence and impact of chronic pain with neuropathic pain symptoms in the general population. Pain Med 2009;10(5):918-29
   PubMed Web of Science ®Google Scholar
• Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002;18(6):350-4
   PubMed Web of Science ®Google Scholar
• Poliakov I, Toth C. The impact of pain in patients with polyneuropathy. Eur J Pain 2011;10:1015-22
   Google Scholar
• Doth AH, Hansson PT, Jensen MP, Taylor RS. The burden of neuropathic pain: a systematic review and meta-analysis of health utilities. Pain 2010;149(2):338-44
   PubMed Web of Science ®Google Scholar
• Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004;5(3):143-9
   PubMed Web of Science ®Google Scholar
• Rodriguez MJ, Garcia AJ. A registry of the aetiology and costs of neuropathic pain in pain clinics: results of the registry of aetiologies and costs (REC) in neuropathic pain disorders study. Clin Drug Investig 2007;27(11):771-82
   PubMed Web of Science ®Google Scholar
• Gore M, Brandenburg NA, Dukes E, Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage 2005;30(4):374-85
   PubMed Web of Science ®Google Scholar
• Argoff CE. The coexistence of neuropathic pain, sleep, and psychiatric disorders: a novel treatment approach. Clin J Pain 2007;23(1):15-22
   PubMed Web of Science ®Google Scholar
• Cornwall A, Donderi DC. The effect of experimentally induced anxiety on the experience of pressure pain. Pain 1988;35(1):105-13
   PubMed Web of Science ®Google Scholar
• Nicholson B, Verma S. Comorbidities in chronic neuropathic pain. Pain Med 2004;5(Suppl 1):S9-27
   PubMed Web of Science ®Google Scholar
• Ohayon MM. Specific characteristics of the pain/depression association in the general population. J Clin Psychiatry 2004;65(Suppl 12):5-9
   PubMed Web of Science ®Google Scholar
• Wilson KG, Eriksson MY, D'Eon JL, Major depression and insomnia in chronic pain. Clin J Pain 2002;18(2):77-83
   PubMed Web of Science ®Google Scholar
• Satzinger G, Hartenstein J, Herrmann M, Cyclic amino acids. Ger. Offen.: DE 2460891, 1976
   Google Scholar
• Tansey B. Huge penalty in drug fraud; Pfizer settles felony case in neurontin off-label promotion. San Francisco Chronicle, May 14, 2004
   Google Scholar
• Mellick GA, Mellick LB. Reflex sympathetic dystrophy treated with gabapentin. Arch Phys Med Rehabil 1997;78(1):98-105
   PubMed Web of Science ®Google Scholar
• Mellick GA, Mellicy LB, Mellick LB. Gabapentin in the management of reflex sympathetic dystrophy. J Pain Symptom Manage 1995;10(4):265-6
   PubMed Web of Science ®Google Scholar
• Mellick LB, Mellick GA. Successful treatment of reflex sympathetic dystrophy with gabapentin. Am J Emerg Med 1995;13(1):96
   PubMed Web of Science ®Google Scholar
• Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001;94(2):215-24
   PubMed Web of Science ®Google Scholar
• Backonja MM. Gabapentin monotherapy for the symptomatic treatment of painful neuropathy: a multicenter, double-blind, placebo-controlled trial in patients with diabetes mellitus. Epilepsia 1999;40(Suppl 6):S57-9; discussion S73-54
   PubMedGoogle Scholar
• Martinez JA, Kasamatsu M, Rosales-Hernandez A, Comparison of central versus peripheral delivery of pregabalin in neuropathic pain states. Mol Pain 2011. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Lyrica Prescribing Information. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=561
   Google Scholar
• Perret D, Luo ZD. Targeting voltage-gated calcium channels for neuropathic pain management. Neurotherapeutics 2009;6(4):679-92
   PubMed Web of Science ®Google Scholar
• Gajraj NM. Pregabalin: its pharmacology and use in pain management. Anesth Analg 2007;105(6):1805-15
   PubMed Web of Science ®Google Scholar
• Field MJ, Oles RJ, Singh L. Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity. Br J Pharmacol 2001;132(1):1-4
   PubMed Web of Science ®Google Scholar
• Fink K, Dooley DJ, Meder WP, Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002;42(2):229-36
   PubMed Web of Science ®Google Scholar
• Micheva KD, Taylor CP, Smith SJ. Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol 2006;70(2):467-76
   PubMed Web of Science ®Google Scholar
• Hutson SM, Berkich D, Drown P, Role of branched-chain aminotransferase isoenzymes and gabapentin in neurotransmitter metabolism. J Neurochem 1998;71(2):863-74
   PubMed Web of Science ®Google Scholar
• Xu Y, Oz G, LaNoue KF, Whole-brain glutamate metabolism evaluated by steady-state kinetics using a double-isotope procedure: effects of gabapentin. J Neurochem 2004;90(5):1104-16
   PubMed Web of Science ®Google Scholar
• Gotz E, Feuerstein TJ, Lais A, Meyer DK. Effects of gabapentin on release of gamma-aminobutyric acid from slices of rat neostriatum. Arzneimittelforschung 1993;43(6):636-8
   PubMed Web of Science ®Google Scholar
• Lucke A, Musshoff U, Kohling R, Gabapentin potentiation of the antiepileptic efficacy of vigabatrin in an in vitro model of epilepsy. Br J Pharmacol 1998;124(2):370-6
   PubMed Web of Science ®Google Scholar
• Parker DA, Ong J, Marino V, Kerr DI. Gabapentin activates presynaptic GABAB heteroreceptors in rat cortical slices. Eur J Pharmacol 2004;495(2-3):137-43
   PubMed Web of Science ®Google Scholar
• Brawek B, Loffler M, Weyerbrock A, Feuerstein TJ. Effects of gabapentin and pregabalin on K+-evoked 3H-GABA and 3H-glutamate release from human neocortical synaptosomes. Naunyn Schmiedebergs Arch Pharmacol 2009;379(4):361-9
   PubMed Web of Science ®Google Scholar
• Vartanian MG, Radulovic LL, Kinsora JJ, Activity profile of pregabalin in rodent models of epilepsy and ataxia. Epilepsy Res 2006;68(3):189-205
   PubMed Web of Science ®Google Scholar
• Bockbrader HN, Wesche D, Miller R, A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 2010;49(10):661-9
   PubMed Web of Science ®Google Scholar
• Su TZ, Feng MR, Weber ML. Mediation of highly concentrative uptake of pregabalin by L-type amino acid transport in Chinese hamster ovary and caco-2 cells. J Pharmacol Exp Ther 2005;313(3):1406-15
   PubMed Web of Science ®Google Scholar
• Piyapolrungroj N, Li C, Bockbrader H, Mucosal uptake of gabapentin (neurontin) vs. pregabalin in the small intestine. Pharm Res 2001;18(8):1126-30
   PubMed Web of Science ®Google Scholar
• Randinitis EJ, Posvar EL, Alvey CW, Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol 2003;43(3):277-83
   PubMed Web of Science ®Google Scholar
• Inc. P. Lyrica® (pregabalin) [package insert]
   Google Scholar
• Toth C. Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. Pain Med 2010;11:456-65
   PubMed Web of Science ®Google Scholar
• Chizh BA, Gohring M, Troster A, Effects of oral pregabalin and aprepitant on pain and central sensitization in the electrical hyperalgesia model in human volunteers. Br J Anaesth 2007;98(2):246-54
   PubMed Web of Science ®Google Scholar
• Bansal D, Bhansali A, Hota D, Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial. Diabet Med 2009;26(10):1019-26
   PubMed Web of Science ®Google Scholar
• Satoh J, Yagihashi S, Baba M, Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial. Diabet Med 2011;28(1):109-16
   PubMed Web of Science ®Google Scholar
• Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008;31(7):1448-54
   PubMed Web of Science ®Google Scholar
• Freynhagen R, Strojek K, Griesing T, Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005;115(3):254-63
   PubMed Web of Science ®Google Scholar
• Hurley RW, Lesley MR, Adams MC, Pregabalin as a treatment for painful diabetic peripheral neuropathy: a meta-analysis. Reg Anesth Pain Med 2008;33(5):389-94
   PubMed Web of Science ®Google Scholar
• Quilici S, Chancellor J, Lothgren M, Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol 2009;9:6
   PubMed Web of Science ®Google Scholar
• Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004;63(11):2104-10
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004;110(3):628-38
   PubMed Web of Science ®Google Scholar
• Richter RW, Portenoy R, Sharma U, Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005;6(4):253-60
   PubMed Web of Science ®Google Scholar
• Sharma U, Griesing T, Emir B, Young JP Jr. Time to onset of neuropathic pain reduction: a retrospective analysis of data from nine controlled trials of pregabalin for painful diabetic peripheral neuropathy and postherpetic neuralgia. Am J Ther 2010;17(6):577-85
   PubMed Web of Science ®Google Scholar
• Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc 2009;84(3):274-80
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Corbin AE, Young JP Jr, Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003;60(8):1274-83
   PubMed Web of Science ®Google Scholar
• Sabatowski R, Galvez R, Cherry DA, Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 2004;109(1-2):26-35
   PubMed Web of Science ®Google Scholar
• van Seventer R, Feister HA, Young JP Jr, Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin 2006;22(2):375-84
   PubMed Web of Science ®Google Scholar
• Stacey BR, Barrett JA, Whalen E, Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief. J Pain 2008;9(11):1006-17
   PubMed Web of Science ®Google Scholar
• Baron R, Mayoral V, Leijon G, 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin 2009;25(7):1663-76
   PubMed Web of Science ®Google Scholar
• Achar A, Chatterjee G, Ray TG, Naskar B. Comparative study of clinical efficacy with amitriptyline, pregabalin, and amitriptyline plus pregabalin combination in postherpetic neuralgia. Indian J Dermatol Venereol Leprol 2010;76(1):63-5
   PubMed Web of Science ®Google Scholar
• Barbarisi M, Pace MC, Passavanti MB, Pregabalin and transcutaneous electrical nerve stimulation for postherpetic neuralgia treatment. Clin J Pain 2010;26(7):567-72
   PubMed Web of Science ®Google Scholar
• Rehm S, Binder A, Baron R. Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study. Curr Med Res Opin 2010;26(7):1607-19
   PubMed Web of Science ®Google Scholar
• Moore RA, Straube S, Wiffen PJ, Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009(3):CD007076
   PubMed Web of Science ®Google Scholar
• Verhaak PF, Kerssens JJ, Dekker J, Prevalence of chronic benign pain disorder among adults: a review of the literature. Pain 1998;77(3):231-9
   PubMed Web of Science ®Google Scholar
• Lawrence RC, Helmick CG, Arnett FC, Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41(5):778-99
   PubMed Web of Science ®Google Scholar
• Elliott AM, Smith BH, Penny KI, The epidemiology of chronic pain in the community. Lancet 1999;354(9186):1248-52
   PubMed Web of Science ®Google Scholar
• Freynhagen R, Baron R. The evaluation of neuropathic components in low back pain. Curr Pain Headache Rep 2009;13(3):185-90
   PubMed Web of Science ®Google Scholar
• Romano CL, Romano D, Bonora C, Mineo G. Pregabalin, celecoxib, and their combination for treatment of chronic low-back pain. J Orthop Traumatol 2009;10(4):185-91
   PubMedGoogle Scholar
• Baron R, Freynhagen R, Tolle TR, The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. Pain 2010;150(3):420-7
   PubMed Web of Science ®Google Scholar
• Finnerup NB. A review of central neuropathic pain states. Curr Opin Anaesthesiol 2008;21(5):586-9
   PubMed Web of Science ®Google Scholar
• Siddall PJ, Cousins MJ, Otte A, Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology 2006;67(10):1792-800
   PubMed Web of Science ®Google Scholar
• Vranken JH, Dijkgraaf MG, Kruis MR, Pregabalin in patients with central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain 2008;136(1-2):150-7
   PubMed Web of Science ®Google Scholar
• Kim JS, Bashford G, Murphy TK, Safety and efficacy of pregabalin in patients with central post-stroke pain. Pain 2011;152(5):1018-23
   PubMed Web of Science ®Google Scholar
• Navarro A, Saldana MT, Perez C, Patient-reported outcomes in subjects with neuropathic pain receiving pregabalin: evidence from medical practice in primary care settings. Pain Med 2010;11(5):719-31
   PubMed Web of Science ®Google Scholar
• Navarro A, Saldana MT, Perez C, A cost-consequences analysis of the effect of pregabalin in the treatment of peripheral neuropathic pain in routine medical practice in primary care settings. BMC Neurol 2011;11:7
   PubMed Web of Science ®Google Scholar
• Saldana MT, Navarro A, Perez C, A cost-consequences analysis of the effect of pregabalin in the treatment of painful radiculopathy under medical practice conditions in primary care settings. Pain Pract 2010;10(1):31-41
   PubMedGoogle Scholar
• Perez C, Saldana MT, Navarro A, Trigeminal neuralgia treated with pregabalin in family medicine settings: its effect on pain alleviation and cost reduction. J Clin Pharmacol 2009;49(5):582-90
   PubMed Web of Science ®Google Scholar
• Saldana MT, Navarro A, Perez C, Patient-reported-outcomes in subjects with painful lumbar or cervical radiculopathy treated with pregabalin: evidence from medical practice in primary care settings. Rheumatol Int 2010;30(8):1005-15
   PubMed Web of Science ®Google Scholar
• Ifuku M, Iseki M, Hidaka I, Replacement of gabapentin with pregabalin in postherpetic neuralgia therapy. Pain Med 2011;12(7):1112-16
   PubMed Web of Science ®Google Scholar
• Tanenberg RJ, Irving GA, Risser RC, Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison. Mayo Clin Proc 2011;86(7):615-26
   PubMed Web of Science ®Google Scholar
• Mishra S, Bhatnagar S, Nirvani Goyal G, A Comparative Efficacy of Amitriptyline, Gabapentin, and Pregabalin in Neuropathic Cancer Pain: A Prospective Randomized Double-Blind Placebo-Controlled Study. Am J Hosp Palliat Care 2011 [Epub ahead of print]
   Web of Science ®Google Scholar
• Perez C, Navarro A, Saldana MT, Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study. Clin Ther 2010;32(7):1357-70
   PubMed Web of Science ®Google Scholar
• Gore M, Sadosky A, Tai KS, Stacey B. A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings. Clin Ther 2007;29(8):1655-70
   PubMed Web of Science ®Google Scholar
• Delahoy P, Thompson S, Marschner IC. Pregabalin versus gabapentin in partial epilepsy: a meta-analysis of dose-response relationships. BMC Neurol 2010;10:104
   PubMed Web of Science ®Google Scholar
• Bramness JG, Sandvik P, Engeland A, Skurtveit S. Does Pregabalin (Lyrica((R))) Help Patients Reduce their Use of Benzodiazepines? A Comparison with Gabapentin using the Norwegian Prescription Database. Basic Clin Pharmacol Toxicol 2010. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Feltner DE, Crockatt JG, Dubovsky SJ, A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003;23(3):240-9
   PubMed Web of Science ®Google Scholar
• Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 2005;25(2):151-8
   PubMed Web of Science ®Google Scholar
• Hindmarch I, Trick L, Ridout F. A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacology (Berl) 2005;183(2):133-43
   PubMed Web of Science ®Google Scholar
• Chiechio S, Zammataro M, Caraci F, Pregabalin in the treatment of chronic pain: an overview. Clin Drug Investig 2009;29(3):203-13
   PubMed Web of Science ®Google Scholar
• Rowbotham M, Harden N, Stacey B, Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998;280(21):1837-42
   PubMed Web of Science ®Google Scholar
• Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001;94(2):215-24
   PubMed Web of Science ®Google Scholar
• Inc. P-D. Neurontin (gabapentin) [package insert]
   Google Scholar
• Norton JW. Gabapentin withdrawal syndrome. Clin Neuropharmacol 2001;24(4):245-6
   PubMed Web of Science ®Google Scholar
• Chalabianloo F, Schjott J. Pregabalin and its potential for abuse. Tidsskr Nor Laegeforen 2009;129(3):186-7
   PubMedGoogle Scholar
• European Medicines Agency (EMA). Lyrica (pregabalin) Scientific Discussion. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000546/human_med_000894.jsp&mid=WC0b01ac058001d124&jsenabled=true. Accessed 8 February 2012
   Google Scholar
• Schwan S, Sundstrom A, Stjernberg E, A signal for an abuse liability for pregabalin–results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol 2010;66(9):947-53
   PubMed Web of Science ®Google Scholar
• Schifano F, D'Offizi S, Piccione M, Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom 2011;80(2):118-22
   PubMed Web of Science ®Google Scholar
• Pregabalin Summary of Product Characteristics. Available from: http://www.medicines.org.uk/emc/medicine/14651. Accessed 8 February 2012
   Google Scholar
• Arif H, Buchsbaum R, Weintraub D, Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 2007;68(20):1701-9
   PubMed Web of Science ®Google Scholar
• Rowan AJ, Ramsay RE, Collins JF, New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005;64(11):1868-73
   PubMed Web of Science ®Google Scholar
• Smith TL, Baldwin A, Cunningham LL Jr, Cook AM. Rash associated with pregabalin use. Ann Pharmacother 2008;42(12):1899-902
   PubMed Web of Science ®Google Scholar
• Huppertz HJ, Feuerstein TJ, Schulze-Bonhage A. Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia 2001;42(6):790-2
   PubMed Web of Science ®Google Scholar
• Heckmann JG, Ulrich K, Dutsch M, Neundorfer B. Pregabalin associated asterixis. Am J Phys Med Rehabil 2005;84(9):724
   PubMed Web of Science ®Google Scholar
• Malaga I, Sanmarti FX. Two cases of painful gynecomastia and lower extremity pain in association with pregabalin therapy. Epilepsia 2006;47(9):1576-9
   PubMed Web of Science ®Google Scholar
• Oaklander AL, Buchbinder BR. Pregabalin-withdrawal encephalopathy and splenial edema: a link to high-altitude illness? Ann Neurol 2005;58(2):309-12
   PubMed Web of Science ®Google Scholar
• Prilipko O, Delavelle J, Seeck M. Pregabalin-withdrawal encephalopathy and splenial edema. Ann Neurol 2006;59(1):214
   PubMed Web of Science ®Google Scholar
• Einarsdottir S, Bjornsson E. Pregabalin as a probable cause of acute liver injury. Eur J Gastroenterol Hepatol 2008;20(10):1049
   PubMed Web of Science ®Google Scholar
• Lindh J. Hepatic adverse effects of pregabalin (Lyrica). Lakartidningen 2010;107(4):194
   PubMedGoogle Scholar
• Dogan S, Ozberk S, Yurci A. Pregabalin-induced hepatotoxicity. Eur J Gastroenterol Hepatol 2011;23(7):628
   PubMed Web of Science ®Google Scholar
• Sendra JM, Junyent TT, Pellicer MJ. Pregabalin-induced hepatotoxicity. Ann Pharmacother 2011;45(6):e32
   PubMedGoogle Scholar
• Eipe N, Penning J. Postoperative respiratory depression with pregabalin: a case series and a preoperative decision algorithm. Pain Res Manag 2011;16(5):353-6
   PubMed Web of Science ®Google Scholar
• Jokela R, Ahonen J, Tallgren M, A randomized controlled trial of perioperative administration of pregabalin for pain after laparoscopic hysterectomy. Pain 2008;134(1-2):106-12
   PubMed Web of Science ®Google Scholar
• Pregabalin: new drug. Very similar to gabapentin. Prescrire Int 2005;14:203-6
   PubMedGoogle Scholar
• Bockbrader HN, Burger P, Knapp L. Pregabalin effect on steady-state pharmacokinetics of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, and tiagabine. Epilepsia 2011;52(2):405-9
   PubMed Web of Science ®Google Scholar
• Cada DJ, Levien D, Baker DE. Pregabalin. Hospital Pharmacy 2006;41(2):157-72
   Google Scholar
• Rosenstock J, Cappelleri JC, Bolinder B, Gerber RA. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 2004;27(6):1318-23
   PubMed Web of Science ®Google Scholar
• Richter RW, Portenoy R, Sharma U, Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005;6(4):253-60
   PubMed Web of Science ®Google Scholar
• Tolle T, Freynhagen R, Versavel M, Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain 2008;12(2):203-13
   PubMed Web of Science ®Google Scholar
• Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol 2008;8:33
   PubMed Web of Science ®Google Scholar
• Baron R, Mayoral V, Leijon G, Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. Curr Med Res Opin 2009;25(7):1677-87
   PubMed Web of Science ®Google Scholar
• Zin CS, Nissen LM, O'Callaghan JP, Preliminary study of the plasma and cerebrospinal fluid concentrations of IL-6 and IL-10 in patients with chronic pain receiving intrathecal opioid infusions by chronically implanted pump for pain management. Pain Med 2010;11(4):550-61
   PubMed Web of Science ®Google Scholar
• Pontari MA, Krieger JN, Litwin MS, Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. Arch Intern Med 2010;170(17):1586-93
   PubMed Web of Science ®Google Scholar
• van Seventer R, Bach FW, Toth CC, Pregabalin in the treatment of post-traumatic peripheral neuropathic pain: a randomized double-blind trial. Eur J Neurol 2010;17(8):1082-9
   PubMed Web of Science ®Google Scholar
• Simpson DM, Schifitto G, Clifford DB, Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Neurology 2010;74(5):413-20
   PubMed Web of Science ®Google Scholar
• Moon DE, Lee DI, Lee SC, Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study. Clin Ther 2010;32(14):2370-85
   PubMed Web of Science ®Google Scholar
• Gray P, Kirby J, Smith MT, Pregabalin in severe burn injury pain: a double-blind, randomised placebo-controlled trial. Pain 2011;152(6):1279-88
   PubMed Web of Science ®Google Scholar
• Semel D, Murphy TK, Zlateva G, Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. BMC Fam Pract 2010;11:85
   PubMed Web of Science ®Google Scholar